Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2451 to 2460 of 2733 total matches.
A Percutaneous Device (MitraClip) for Mitral Regurgitation
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
surgery for mitral valve dysfunction.1
At 4 years, the primary composite endpoint persisted
in 40 ...
The FDA has approved the use of a transcatheter
mitral valve device (MitraClip – Abbott) for percutaneous
treatment of significant symptomatic degenerative
mitral regurgitation (grade 3-4+) in patients who
are at prohibitive risk for mitral valve surgery. It is the
first percutaneous nonsurgical treatment approved for
this indication.
Durlaza - A 24-Hour Extended-Release Aspirin
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016 (Issue 1486)
at the
end of the 24-hour dosing interval.1 An ER formulation
that releases acetylsalicylic acid (ASA) over ...
The FDA has approved Durlaza (New Haven
Pharmaceuticals), a 24-hour extended-release (ER)
aspirin formulation available only by prescription, for
secondary prevention of myocardial infarction (MI)
and stroke.
Table: Over the Counter At-Home Tests for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Oct 20, 2021 (Issue 5041)
Overall: 92%/98% No Yes6 75.00
Test Kit (Lucira) minutes Symptomatic: 94%/98% (1 ct)7
Asymptomatic: 90 ...
View the Table: Over the Counter At-Home Tests for COVID-19
Med Lett Drugs Ther. 2021 Oct 20;63(5041):e1 doi:10.58347/tml.2021.5041a | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
)
5.8 g/teaspoon powder; 5.8 g
packets; 1.8 g caps; 2 g wafers
$29.00
10-35 g/day in 2-3 divided ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721e | Show Introduction Hide Introduction
Lunsotogene Parvec (Otarmeni) for Hearing Loss (online only)
The Medical Letter on Drugs and Therapeutics • Oct 12, 2026 (Issue 1765)
otoferlin.1
CLINICAL STUDIES — Accelerated approval of lunsotogene
parvec was based on the results ...
Lunsotogene parvec (Otarmeni – Regeneron), an adeno-associated
viral vector-based gene therapy, has received
accelerated approval from the FDA for treatment of severe-to-profound or profound sensorineural hearing loss (any
frequency >90 decibels hearing level [dB HL]) in patients with
confirmed variants in both copies of the otoferlin (OTOF)
gene. It is the first gene therapy to be approved in the US for
genetic hearing loss.
Med Lett Drugs Ther. 2026 Oct 12;68(1765):e169 doi:10.58347/tml.2026.1765d | Show Introduction Hide Introduction
Comparison Chart: Antiviral Drugs for Seasonal Influenza (online only)
The Medical Letter on Drugs and Therapeutics • Nov 09, 2026 (Issue 1767)
-approved for chemoprophylaxis of influenza in patients ≥1 year old $48.00
152.00
Peramivir – Rapivab ...
View the Comparison Chart: Antiviral Drugs for Seasonal Influenza
Med Lett Drugs Ther. 2026 Nov 9;68(1767):e180-3 doi:10.58347/tml.2026.1767c | Show Introduction Hide Introduction
In Brief: Statins for Primary Prevention in Older Adults
The Medical Letter on Drugs and Therapeutics • Nov 23, 2026 (Issue 1768)
) are the
drugs of choice for lowering low-density lipoprotein
cholesterol (LDL-C).1 They reduce the risk ...
HMG-CoA reductase inhibitors (statins) are the drugs of
choice for lowering low-density lipoprotein cholesterol
(LDL-C). They reduce the risk of primary and secondary
atherosclerotic cardiovascular disease (ASCVD) events and
death, but data supporting their efficacy and safety in older
adults have been lacking. Guidelines recommend weighing
the potential risks and benefits when deciding whether to
start or stop statin therapy for primary prevention in adults
>75 years old. Results of a trial evaluating statin initiation
for primary prevention of ASCVD in older persons have
recently...
Med Lett Drugs Ther. 2026 Nov 23;68(1768):191 doi:10.58347/tml.2026.1768e | Show Introduction Hide Introduction
Corrections: Drugs for Diabetes & Another Insulin Glargine (Basaglar) for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
Corrections
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)
In the 4th paragraph of the GLP-1 ...
Drugs for Diabetes (Med Lett Drugs Ther 2017; 59:9)In the 4th paragraph of the GLP-1 receptor agonists section, we mistakenly stated that Xultophy 100/3.6 is a combination of insulin degludec and albiglutide; Xultophy 100/3.6 is a combination of insulin degludec and liraglutide.Another Insulin Glargine (Basaglar) for Diabetes (Med Lett Drugs Ther 2017; 59:3)In the Dosage and Administration section, we removed the word "syringe" to describe Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.Download complete U.S. English...
Smallpox Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003 (Issue 1147)
)
FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 1
Vaccination — Smallpox ...
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination (https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be...
Alendronate and Risedronate
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005 (Issue 1207)
% of the alendronatetreated women.
1
After 5 years, placebo-treated
patients were discharged from the study. Patients ...
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.
